Publication: A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX
Issued Date
2020-02-01
Resource Type
ISSN
22110356
22110348
22110348
Other identifier(s)
2-s2.0-85074776467
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Multiple Sclerosis and Related Disorders. Vol.38, (2020)
Suggested Citation
Thanapon Songthammawat, Tayanan Srisupa - Olan, Sasitorn Siritho, Kulvara Kittisares, Jiraporn Jitprapaikulsan, Chanjira Sathukitchai, Naraporn Prayoonwiwat A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Multiple Sclerosis and Related Disorders. Vol.38, (2020). doi:10.1016/j.msard.2019.101506 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/49634
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX
Abstract
© 2019 Elsevier B.V. Background: : Our previous retrospective study demonstrated that NMOSD patients with an acute attack who did not respond to IVMP alone, however, showed further significant improvement after treatment with PLEX at 6 month-follow-up. Objective: : To compare the efficacy between treatments with intravenous methylprednisolone (IVMP) with subsequent add-on plasma exchange (PLEX) and a combination of simultaneous IVMP and PLEX in neuromyelitis optica spectrum disorders (NMOSD) patients with a severe acute attack. Method: We conducted a prospective, randomized, controlled, pilot study of the treatments for a severe acute attack in NMOSD patients. Results: : There were eleven AQP4-positive NMOSD patients in the study. One received only IVMP, five received IVMP with subsequent add-on PLEX treatment, and the other five received simultaneous IVMP and PLEX treatment. The attacks comprised myelitis (57.1%) and optic neuritis (42.9%). Both treatments with IVMP followed by subsequent add-on PLEX when needed (not-respond to IVMP treatment) and a combination treatment of simultaneous IVMP+PLEX from the outset showed clinical improvement measured by EDSS at 6 months follow-up, compared to those at the attacks (p-value = 0.07 in IVMP add-on PLEX group and p-value = 0.05 in IVMP+PLEX group), respectively. Although, a trend of a better outcome stratified by EDSS toward early PLEX initiation with IVMP+PLEX treatment was observed at 6 months follow-up, however not significantly. Conclusion: : Early treatment with PLEX should be encouraged especially in NMOSD with a severe acute attack.